The BioStrand history:

• 2014 Idea born
• 02/2019 Legal incorp.
• 05/2020 € 2 M seed investment by corporate VC
• 06/2020 € 235 K VLAIO grant
• Currently +10 employees
• 1 patent pending, several patents in preparation

Our mission: We are passionate about building the next generation technology that makes omics data analysis truly effective.

Our vision: Completely integrating sequence and 3D structure analysis will revolutionise protein structure and function prediction and boost developments in precision medicine and biotechnology.

About the pitch

BioStrand has developed disruptive technology for omics data analysis and AI discovery. By combining sequence and structure through our HYFTs™ patterns, we bring structure and function prediction to the next level. The HYFTs™ are signature sequences across species that serve as structural anchor points and carry a multitude of information layers. All those patterns make up the HYFT^TM information network that serves as a pan genomic graph to be searched in a Google-like way. With relevant meta data such as clinical data, disease pathways or compound data, our proprietary AI toolbox revolutionises identification and prediction of very specific targets and leads for drugs and crop protection product development, biomarkers and assay design. The paradigm shift in algorithmic approach allows for a completely integrated workflow, ultra-scalability, speed and accuracy of data analysis. By solving the current bottlenecks in bioinformatics BioStrand unlocks the true potential present in omics data boosting evolutions in biotechnology and precision medicine.